24 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, May 7, 2021
Slide 1: MLP Care Q1 2021 Presentation
MLP CARE Q1 2021 PRESENTATION M AY 7 , 2 0 2 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 4: At a Glance: MLP Care Q1 2021 Financial Highlights
At a Glance: MLP Care Q1 2021 Financial Highlights Adj. EBITDA Revenue TL 1,211 m TL 346 m 24% Growth 47% Growth Robust revenue growth continued y-o-y despite (Q1 2020: TL 979 m) (Q1 2020: TL 235 m) the challenges of pandemic and high base of the last year (January-February 2020) EBITDA margin s
Slide 5: # of People with Top-up Insurance Close to 1.8 million
# of People with Top-up Insurance Close to 1.8 million # of People with Top-up Insurance in Turkey (in thousand) 03.2021; 1,791 03.2020; 1,218 CAGR (2014-2020) %71.0 Top-up LTM Top-up Addition Linear (Top-up) # of People with Insurance in Turkey (in thousand) LTM Addition to Number of People with To
Slide 6: At a Glance: MLP Care Operational Highlights
At a Glance: MLP Care Operational Highlights Two brands and one concept targeting three different price points with The largest hospital group in 30 Hospitals in consistently outstanding medical service Total Turkey quality Established in 1993, listed on BIST in 2018 ~17,000 Staff 1 ~6,000 Beds in T
Slide 7: Our Growth Strategy is Intact
Our Growth Strategy is Intact MLP Care continues its asset light growth strategy Growing our existing business by increasing capacity utilization at large hospitals Expanding in metropolitans through mid- large scale hospitals (min. 100 bed capacity) Quick EBITDA ramp-up through leveraging MLP Care’
Slide 8: Planned Opening and M&A's
Planned Opening and M&A’s # of Hospitals Liv Hospital İstanbul Target M&A’s (Planned) 5 1 25 Medical Park Liv Hospital 2021 Additions Liv Hospital Location İstanbul Evaluating opportunistic M&A’s in Opening Date ~ Q2 2021 Turkey 8
Slide 9: Burcu Öztürk, CFO
BURCU OZTURK CFO MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 10: Revenue Increased 24% in Q1 2021 despite the COVID-19 Impact
Revenue Increased 24% in Q1 2021 despite the COVID-19 Impact Revenue (TLm) 23.7% 1,211 979 Q1 2020 Q1 2021 Denotes growth of Revenue vs. the same period of the last year 10
Slide 11: Accelerated Revenue Growth in Q1 2021
Accelerated Revenue Growth in Q1 2021 Q1 2021 (53%) 9% Revenue from SSI was up by 33% in Q1 2021 3% (SSI Insurance allows for a wide addressable 9% 33% market, which is c.98% of the total population) 26% Self pay increased by 25% in Q1 2021 Revenue from PMI, Top-up & Contracted Institutions in
Slide 12: Revenue Growth Supported by High Domestic Revenues
Revenue Growth Supported by High Domestic Revenues Domestic Patient Medical Tourism Ancillary Business Revenues Revenues 32.2% 19.9% 32.4% 9.2% (52.7%) 1,068 109 72 100 807 34 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Revenue Growth Accelerated in Gradual recovery in Medical Decrease in Labora
Slide 13: Strong Improvement in Both ARPV and ARPP in Q1 2021
Strong Improvement in Both ARPV and ARPP in Q1 2021 Outpatient Revenues (TLm) Inpatient Revenues (TLm) 30.8% 33.4% 38.3% 48.3% (7.5%) (14.8%) 230 (25) 126 432 (71) 636 330 477 Q1 2020 Volume & Mix Price Q1 2021 Q1 2020 Volume & Mix Price Q1 2021 Average Revenue Per Visit (ARPV) Average Revenue Per P
Slide 14: EBITDA Up by 47% in Q1 2021 supported by prudent cost management
EBITDA Up by 47% in Q1 2021 supported by prudent cost management EBITDA (TLm) 47.1% 43.6% 28.6% 25.8% 346 313 22.3% 24.0% 235 218 Q1 2020 1 Q1 20211 Q1 2020 2 Q1 2021 2 1 Adj. EBITDA: EBITDA TFRS adjustments that have no cash impact on relevant period and one-off income/expense items 2 Adj. EBITDA:
Slide 15: Net Profit Up by 30% in Q1 2021
Net Profit Up by 30% in Q1 2021 Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 30.2% 30.3% 6.6% 5.4% 6.3% 80 5.1% 66 61 50 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Denotes growth of Net Profit and Net Profit Allocated to Equity Holders of the Parent vs. the same period of the las
Slide 16: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin Adj. EBITDA Margin 24.0% 28.6% Material costs as a % of revenue declined in Q1 2021 0.9% due to decrease in the share of laboratory business 0.9% which
Slide 17: Long Position in FX Net Debt
Long Position in FX Net Debt FX BASED NET DEBT 1 (in EUR m) GROSS DEBT PERCENTAGE 2020 Q1 2021 EUR30m EUR32m EUR41m equivalent of equivalent of equivalent of Cash Balance 579mTL Cash Balance 375mTL FX Cash FX Cash FX Cash Balance Balance Balance 15% 22% 78% 85% 65 51 Net Debt 2,117mTL Net Debt 2,050
Slide 18: Total Capex Decreased, Operating Cash Flow Improved
Total Capex Decreased, Operating Cash Flow Improved Maintenance Capex (TLm) Total Capex (TLm) Operating Cash Flow / EBITDA Free Cash Flow / EBITDA 93.2% 3.7% 3.6% 87.4% 80.6% 2.0% 2.0% 72.0% 322 279 43 205 36 169 20 24 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 Q1 2020 Q1 2021 % of Revenue % of
Slide 19: Q&A
Q&A MLPCARE MEDICALPARK | Lit/nosprtaL
Slide 20: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 21: Thank You!
Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/
Slide 22: Historical Balance Sheet
Historical Balance Sheet Unaudited Audited TLm March 31, 2021 December 31, 2020 Cash and cash equivalents 579 375 Trade receivables 1,217 1,155 Inventory 109 113 Short term other assets 603 542 Current assets 2,508 2,185 Tangible and intangible fixed assets 1,439 1,441 Right of use assets 296 257 De
Slide 23: Historical P&L Statements
Historical P&L Statements Unaudited Unaudited Change (%) TLm Q1 2021 Q1 2020 Revenue 1,211 979 23.7% Cost of service (-) (908) (750) 21.1% Gross profit 303 229 32.4% General administration expenses (-) (85) (74) 14.6% Other income from operations 85 82 3.2% Other expenses from operations (-) (57) (6
Slide 24: Reconciliation from Reported EBITDA to Adjusted EBITDA
Reconciliation from Reported EBITDA to Adjusted EBITDA TLm Q1 2021 Q1 2020 Net profit / (loss) 80 61 Tax (income) from operations 35 25 Depreciation and amortization of tangible and intangible fixed assets 73 62 Total interest expenses/(income) and fair value differences of derivative instruments 12